Tenax Therapeutics
TENX
81 hedge funds and large institutions have $341M invested in Tenax Therapeutics in 2026 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 26 increasing their positions, 5 reducing their positions, and 1 closing their positions.
3,300% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 1
420% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 5
312.92% more ownership
Funds ownership: 154.5% → 467.42% (+313%)
297% more capital invested
Capital invested by funds: $85.9M → $341M (+$255M)
65% more funds holding
Funds holding: 49 → 81 (+32)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$39.9M |
| 2 |
VA
VR Adviser
New York
|
+$22.7M |
| 3 |
Janus Henderson Group
London,
|
+$22.3M |
| 4 |
PA
Perceptive Advisors
New York
|
+$13.6M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DP
Diadema Partners
Morristown,
New Jersey
|
-$858K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$732K |
| 3 |
RI
RTW Investments
New York
|
-$110K |
| 4 |
PAP
Persistent Asset Partners
Hong Kong
|
-$95.9K |
| 5 |
QC
Quadrature Capital
London,
United Kingdom
|
-$70K |
TENX Hedge Fund Activity: Q1 2026 in Review
81 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q1 2026, worth a combined $341M — up 297% from $85.9M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new TENX positions and 1 closed out — a net gain of 33 holders — while 26 added to existing stakes and 5 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $39.9M. The largest seller was Diadema Partners, cutting an estimated $858K.
- 81 institutional investors held Tenax Therapeutics (TENX) as of Q1 2026, up from 49 in Q4 2025.
- Funds reported $341M of Tenax Therapeutics stock for Q1 2026, up 297% quarter-over-quarter.
- 34 funds opened new Tenax Therapeutics positions in Q1 2026 and 1 closed out, a net change of +33 holders.
- The largest Tenax Therapeutics buyer in Q1 2026 was T. Rowe Price Associates, an estimated $39.9M added.
- The largest Tenax Therapeutics seller in Q1 2026 was Diadema Partners, an estimated $858K sold.
Based on aggregated 13F filings for Q1 2026.